聚二磷酸腺苷核糖聚合酶抑制剂在晚期卵巢癌中的研究进展

Progress of poly(ADP-ribose)polymerase inhibitor in advanced ovarian cancer

卵巢癌目前是威胁女性生命健康的主要疾病之一,病死率位居女性生殖系统恶性肿瘤第1位。由于早期病变不易被发现,75%以上患者确诊时已是晚期。晚期卵巢癌是指国际妇产科协会分期Ⅲ~Ⅳ期,预后极差,5年生存率不足50%。近年来,关于卵巢癌维持治疗的探索如火如荼。大量研究表明,聚二磷酸腺苷核糖聚合酶(PARP)抑制剂用于晚期卵巢癌患者的疗效显著,因此PARP抑制剂逐渐成为卵巢癌治疗的重要一环,其适应证受到广大临床医师的关注。文章就PARP抑制剂在晚期卵巢癌中的研究进展进行综述。

At present,ovarian cancer is one of the main diseases threatening women's life and health.The mortality ranks first among female reproductive system malignant tumors.Due to the hidden onset,more than 75%of them are at advanced stage once diagnosed.Advanced ovarian cancer is characterized with the Federation International of Gynecology and Obstetrics(FIGO)stageⅢ-Ⅳ,very poor prognosis and the 5-year survival rate less than 50%.In recent years,the exploration of maintenance treatment of ovarian cancer is in full swing.A large number of studies show that poly(ADP-ribose)polymerase(PARP)inhibitors are effective in patients with advanced ovarian cancer.Therefore,PARP inhibitors have gradually become an important part for treatment of ovarian cancer,and the indications have also been concerned by clinicians.This paper reviews the application of PARP inhibitors in advanced ovarian cancer.